CFA
AST

CT Financial Advisors’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

CT Financial Advisors’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$24 Hold
7
– – ﹤0.01% 638
2016
Q4 		$32 Buy
+7
New +$29 ﹤0.01% 635
2015
Q1 		– Sell
-34
Closed -$110 – 649
2014
Q4 		$110 Buy
+34
New +$137 ﹤0.01% 516

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

CT Financial Advisors's AST Position: Q1 2017 in Review

CT Financial Advisors held its Asterias Biotherapeutics Inc. Series A (AST) position steady in Q1 2017 at 7 shares worth $24. The position accounts for ﹤0.01% of the portfolio, ranked #638.

CT Financial Advisors first reported a position in AST in Q4 2014 and has held it in 3 quarters since. The position peaked at $110 in Q4 2014. 66 funds tracked by Wall St. Rank hold AST as of Q1 2017.

  • CT Financial Advisors held 7 shares of Asterias Biotherapeutics Inc. Series A worth $24 as of Q1 2017.
  • CT Financial Advisors left its Asterias Biotherapeutics Inc. Series A share count unchanged in Q1 2017.
  • Asterias Biotherapeutics Inc. Series A made up ﹤0.01% of CT Financial Advisors's portfolio in Q1 2017, its #638 holding.
  • CT Financial Advisors first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and has held it in 3 quarters since.
  • CT Financial Advisors's Asterias Biotherapeutics Inc. Series A position peaked at $110 in Q4 2014.
  • 66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.